ADC Therapeutics
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 30.8m | 191m | 63.2m | 66.2m | 75.9m | 99.2m |
| % growth | - | - | 519 % | (67 %) | 5 % | 15 % | 31 % |
| EBITDA | (217m) | (212m) | (89.8m) | (133m) | (104m) | (87.3m) | - |
| % EBITDA margin | - | (687 %) | (47 %) | (210 %) | (157 %) | (115 %) | - |
| Profit | (224m) | (209m) | (142m) | (218m) | (144m) | (145m) | (135m) |
| % profit margin | - | (678 %) | (74 %) | (345 %) | (218 %) | (191 %) | (136 %) |
| EV / revenue | - | 32.2x | 0.4x | -0.3x | 2.1x | 1.9x | 1.3x |
| EV / EBITDA | -8.8x | -4.7x | -0.9x | 0.1x | -1.4x | -1.7x | - |
| R&D budget | 129m | 144m | 171m | 116m | - | - | - |
| R&D % of revenue | - | 466 % | 90 % | 183 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | Corporate spinout | |
$50.0m | Series A | ||
$40.0m | Early VC | ||
$80.0m | Growth Equity VC | ||
$105m | Growth Equity VC | ||
* | $200m | Growth Equity VC | |
| N/A | $76.0m | Series E | |
| N/A | $25.0m | Series E | |
* | N/A | $268m Valuation: $1.3b 555.5x EV/LTM Revenues -11.4x EV/LTM EBITDA | IPO |
* | $175m | Post IPO Debt | |
* | N/A | $60.0m | Post IPO Equity |
* | N/A | $105m | Post IPO Equity |
| Total Funding | €524m | ||
Recent News about ADC Therapeutics
EditADCT Therapeutics is a biopharmaceutical company that specializes in the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of cancer. ADCs are a type of targeted therapy that delivers potent drugs directly to cancer cells, minimizing damage to healthy cells. The company's primary focus is on hematologic malignancies, or cancers that affect the blood, bone marrow, and lymph nodes.
ADCT Therapeutics operates in the global pharmaceutical market, specifically within the oncology sector. Its clients are primarily healthcare providers and patients suffering from cancer. The company's business model revolves around the research, development, and commercialization of its ADCs. It generates revenue through the sales of its approved drugs and also through partnerships with other pharmaceutical companies for the development and commercialization of its drug candidates.
The company is committed to ethical practices, innovation, accountability, collaboration, and proactive action. It offers competitive salaries, bonuses, and comprehensive benefits programs to its employees, including a 401-K savings plan for US-based employees and a contributory pension for European-based employees.
ADCT Therapeutics is a publicly-traded company, and it recently reported its Q3 2023 financial results. The company's leadership participates in healthcare conferences and workshops, and it supports initiatives like The Leukemia and Lymphoma Society's Light the Night Walk.
Keywords: Biopharmaceutical, Antibody-Drug Conjugates, Cancer Treatment, Hematologic Malignancies, Global Pharmaceutical Market, Oncology, Research and Development, Healthcare Providers, Ethical Practices, Employee Benefits.